Abstract Background Although EGFR-TKI is the preferred treatment for NSCLC patients with
sensitive mutations, subsequent drug resistance is almost inevitable. The specific …

Background Treatment-naive epidermal growth factor receptor (EGFR) T790M mutation is
more inclined to coexist with L858R than with 19 del in non-small cell lung cancer (NSCLC) …

The most common event responsible for resistance to first-and second-generation (1st and
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …

After sequential treatment with first-and third-generation EGFR tyrosine kinase inhibitors
(TKIs), EGFR-mutant non-small cell lung cancers frequently harbor multiple resistance …

Abstract Objectives Although T790M mutation is considered to be the major mechanism of
acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Abstract Background The secondary T790M mutation accounts for more than 50% of
acquired tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutated non–small …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

In Taiwan, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib, erlotinib, and afatinib are served as first-line therapy for non-small lung cell cancer …

Background EGFR tyrosine kinase inhibitors (TKIs) have shifted the treatment paradigm in
advanced EGFR‐mutant non–small cell lung cancer (NSCLC). However, patients who are …

SUMMARY T790M in epidermal growth factor receptor (EGFR) accounts for about 50% of
the acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with non–small …